Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Crosses Above 200 Day Moving Average – What’s Next?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.33 and traded as high as $3.86. Cumberland Pharmaceuticals shares last traded at $3.59, with a volume of 193,907 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Wall Street Zen raised Cumberland Pharmaceuticals to a “hold” rating in a report on Saturday, January 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Stock Performance

The stock has a fifty day simple moving average of $3.78 and a two-hundred day simple moving average of $3.33. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.23. The stock has a market capitalization of $53.71 million, a price-to-earnings ratio of -14.96 and a beta of -0.52.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter. Cumberland Pharmaceuticals had a negative net margin of 8.06% and a positive return on equity of 5.13%. The business had revenue of $8.29 million for the quarter.

Institutional Trading of Cumberland Pharmaceuticals

Several large investors have recently modified their holdings of CPIX. Heron Bay Capital Management acquired a new position in shares of Cumberland Pharmaceuticals during the 2nd quarter valued at $111,000. Dimensional Fund Advisors LP increased its stake in Cumberland Pharmaceuticals by 11.1% in the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after purchasing an additional 27,980 shares in the last quarter. XTX Topco Ltd bought a new stake in Cumberland Pharmaceuticals in the second quarter valued at $34,000. Two Sigma Investments LP raised its holdings in shares of Cumberland Pharmaceuticals by 16.5% during the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,326 shares during the period. Finally, Bridgeway Capital Management LLC boosted its position in shares of Cumberland Pharmaceuticals by 2.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after purchasing an additional 4,200 shares in the last quarter. Institutional investors and hedge funds own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.